Abstract
Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Anti-Cancer Agents in Medicinal Chemistry
Title: The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies
Volume: 8 Issue: 6
Author(s): Vineet Pande, Maria J. Ramos and Federico Gago
Affiliation:
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Abstract: Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Export Options
About this article
Cite this article as:
Pande Vineet, Ramos J. Maria and Gago Federico, The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133056
DOI https://dx.doi.org/10.2174/187152008785133056 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Natural Anticancer Agent Thaspine Targets Human Topoisomerase IB
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Current Drug Targets Carotenoids and Prostate Cancer Risk
Mini-Reviews in Medicinal Chemistry Rapid Characterization of a Novel Taspine Derivative-HMQ1611 Binding to EGFR by a Cell Membrane Chromatography Method
Combinatorial Chemistry & High Throughput Screening The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Lymnaea EGF and Gigantoxin I, Novel Invertebrate Members of the Epidermal Growth Factor Family
Current Pharmaceutical Design Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives
Anti-Cancer Agents in Medicinal Chemistry Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Advances on 3-Hydroxyflavone Derivatives: Structures and Properties
Mini-Reviews in Medicinal Chemistry Polymers and Biopolymers as Drug Delivery Systems in Nanomedicine
Recent Patents on Nanomedicine Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Meet Our Sectional Editor
Anti-Cancer Agents in Medicinal Chemistry Intracellular ROS Generation Mediates Maleimide-induced Cytotoxicity in Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Liquid Crystal Nanodispersions Enable the Cutaneous Delivery of Photosensitizer for Topical PDT: Fluorescence Microscopy Study of Skin Penetration
Current Nanoscience LNA Antisense: A Review
Current Physical Chemistry Synthesis, In Vitro Biological Screening and Molecular Docking Studies of Novel Camphor-Based Thiazoles
Medicinal Chemistry